Ngwaahịa

Fluorouracil ọgwụ antineoplastic bụ ọgwụ nke fluorouracil.Thymidine phosphorylase dị na anụ ahụ tumor na-arụ ọrụ na ya iji mee ka ọ ghọọ fluorochemicalbook uracil na tumor, si otú ahụ na-enwe mmetụta mgbochi tumor.Nkọwapụta mgbochi tumor ya siri ike, na nsi ya dị ala.A na-eji ụlọ ọgwụ eme ihe maka ọrịa kansa afọ, ọrịa cancer colorectal, ọrịa ara ara, ọnụọgụ mgbaghara nwere ike iru karịa 30%.

Ọdịmma nke chemotherapy sistemu maka mgbasa peritoneal nke ọrịa kansa afọ ka amabeghị.A na-enyocha ịdị irè nke paclitaxel kwa izu na-ejikọta ya na doxifluridine (5'-DFUR) na ndị ọrịa cancer na-arịa ọrịa afọ na-arịa ọrịa na-adịghị mma.Ọgwụgwọ ahụ bụ paclitaxel intravenously (iv) nke a na-enye na 80 mg / m (2) na ụbọchị 1, 8 na 15 kwa izu anọ, na doxifluridine na-enye ọnụ na 533 mg / m (2) na ụbọchị 1-5 kwa izu.A na-ekpebi ọnụego nzaghachi maka ndị ọrịa nwere ascites dabere na nhazi ọkwa Japanese nke Gastric Carcinoma.Ọzọkwa, a tụrụ uche nke paclitaxel na ascites. A na-enyocha ndị ọrịa iri abụọ na anọ.Ọnụ ọgụgụ nzaghachi (RR) bụ 41.7%, gụnyere nkwụsị zuru ezu (CR) na remission (PR) na ndị ọrịa 4 na 6, n'otu n'otu.A na-echekwa ntinye nke paclitaxel na ascites n'etiti 0.01 μM na 0.05 μM ruo awa 72.Ogologo nlanarị nke etiti (OS) bụ ụbọchị 215, yana ọnụego nlanarị otu afọ bụ 29.2%.Achọpụtaghị oke nsi na-egbu egbu. Paclitaxel kwa izu na ngwakọta na doxifluridine dị irè maka ndị ọrịa cancer afọ na-arịa ọrịa ascites na-adịghị mma na profaịlụ nsi na-anabata.